Zacks Investment Management Meira G Tx Holdings PLC Transaction History

Zacks Investment Management

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$5.78 - $7.33 $87,908 - $111,481	15,209 New	15,209 $92,000
Q1 2022 May 13, 2022	SELL	$13.42 - $23.38 $282,048 - $491,377	-21,017 Closed	0 $0
Q4 2021 Feb 15, 2022	SELL	$12.78 - $23.74 $198,038 - $367,875	-15,496 Reduced 42.44%	21,017 $499,000
Q3 2021 Nov 15, 2021	SELL	$11.73 - $16.08 $2,991 - $4,100	-255 Reduced 0.69%	36,513 $481,000
Q2 2021 Aug 16, 2021	BUY	$12.85 - $16.2 $3,276 - $4,131	255 Added 0.7%	36,768 $570,000
Q1 2021 May 17, 2021	SELL	$13.84 - $17.8 $62,626 - $80,545	-4,525 Reduced 11.03%	36,513 $527,000
Q4 2020 Feb 16, 2021	SELL	$12.4 - $17.6 $146,344 - $207,715	-11,802 Reduced 22.34%	41,038 $621,000
Q3 2020 Nov 16, 2020	SELL	$11.59 - $14.93 $46,128 - $59,421	-3,980 Reduced 7.0%	52,840 $700,000
Q2 2020 Aug 14, 2020	BUY	$11.79 - $15.97 $157,455 - $213,279	13,355 Added 30.73%	56,820 $711,000
Q4 2019 Feb 14, 2020	BUY	$13.91 - $21.48 $604,598 - $933,628	43,465 New	43,465 $870,000

100

45.4M

19.2K

31K

Ticker MGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,010,700
Market Cap $283M
Description
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative dise...

Get notified when there are updates to the investment portfolio of Zacks Investment Management, based on Form 13F filings with the SEC.

Stay updated on Zacks Investment Management with notifications on news.